Genmab (NASDAQ:GMAB) presented new data at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Monday, demonstrating that its investigational antibody-drug conjugate (ADC), rinatabart sesutecan (Rina-S), can be safely combined with bevacizumab in patients with advanced ovarian cancer.
The findings, derived from the Phase 1/2 RAINFOL-01 study, indicate that the combination therapy maintains a safety profile consistent with the individual agents, with no new or unexpected toxicities reported.
The study is a critical component of Genmab's strategy to move Rina-S into broader treatment settings for gynecologic malignancies.
In the evaluated cohort, 40 patients with recurrent ovarian cancer received Rina-S (120 mg/m²) alongside bevacizumab every three weeks.
The most common treatment-emergent adverse events included nausea (80%), fatigue (67.5%), and anemia (55%).
Notably, investigators reported an absence of ocular toxicities, peripheral neuropathy, or interstitial lung disease—side effects that have historically complicated the development of other ADC therapies.
Rina-S is an ADC designed to target folate receptor alpha (FRα), a protein highly expressed in several solid tumors, including ovarian and endometrial cancers.
It utilizes a topoisomerase I (TOPO1) inhibitor payload to deliver targeted cell death.
Genmab is currently accelerating the candidate through multiple late-stage trials, including three Phase 3 studies (RAINFOL-02, -03, and -04) covering platinum-resistant, platinum-sensitive, and endometrial cancer populations.
Beyond gynecologic cancers, Genmab is also evaluating the candidate in a Phase 2 study for non-small cell lung cancer (NSCLC).